Novel thiazole amine class tyrosine kinase inhibitors induce apoptosis in human mast cells expressing D816V KIT mutation

Cancer Letters

Volumn 353, Issue 1, 2014, Pages 115-123

  Jin, Yanli ^a   Ding, Ke ^b   Wang, Deping ^b   Shen, Mengjie ^b   Pan, Jingxuan ^a,c,d  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

D816V mutation; Imatinib resistance; KIT; Tyrosine kinase inhibitor

Indexed keywords

3 METHYL N [3 (4 METHYL 1H IMIDAZOL 1 YL) 5 (TRIFLUOROMETHYL)PHENYL] 4 [4 (PYRIDIN 3 YL)THIAZOL 2 YLAMINO]BENZAMIDE; BETA CATENIN; DASATINIB; MIDOSTAURIN; N [3 (1H 1,2,4 TRIAZOL 1 YL) 5 (TRIFLUOROMETHYL)PHENYL] 3 METHYL 4 [4 (PYRIDIN 3 YL)THIAZOL 2 YLAMINO]BENZAMIDE; PROTEIN MCL 1; PROTEIN TYROSINE KINASE INHIBITOR; STAT3 PROTEIN; STAT5 PROTEIN; STEM CELL FACTOR RECEPTOR; SURVIVIN; UNCLASSIFIED DRUG; AMINE; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; THIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MAST CELL; MOUSE; MUTATION; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; D816V MUTATION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; GENOTYPE; IMATINIB-RESISTANCE; KIT; MASTOCYTOMA; METABOLISM; MOLECULARLY TARGETED THERAPY; NUDE MOUSE; PATHOLOGY; PHENOTYPE; PHOSPHORYLATION; RNA INTERFERENCE; SYNTHESIS; TIME; TRANSPLANTATION; TUMOR CELL LINE;

D816V MUTATION; IMATINIB-RESISTANCE; KIT; TYROSINE KINASE INHIBITOR;

AMINES; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; GENOTYPE; HUMANS; MALE; MAST CELLS; MASTOCYTOMA; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR TARGETED THERAPY; MUTATION; PHENOTYPE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; RNA INTERFERENCE; SIGNAL TRANSDUCTION; THIAZOLES; TIME FACTORS; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908375511     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.07.017     Document Type: Article

References (30)

1. Arock M., Valent P. Pathogenesis, classification and treatment of mastocytosis: state of the art in and future perspectives. Expert Rev. Hematol. 2010, 3:497-516.
2. Georgin-Lavialle S., Lhermitte L., Dubreuil P., Chandesris M.O., Hermine O., Damaj G. Mast cell leukemia. Blood 2013, 121:1285-1295.
3. Lim K.H., Tefferi A., Lasho T.L., Finke C., Patnaik M., Butterfield J.H., McClure R.F., Li C.Y., Pardanani A. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 2009, 113:5727-5736.
4. Horny H.P., Sotlar K., Valent P. Mastocytosis: state of the art. Pathobiology: journal of immunopathology. Mol. Cell. Biol. 2007, 74:121-132.
5. Pardanani A. Systemic mastocytosis in adults: 2012 update on diagnosis, risk stratification, and management. Am. J. Hematol. 2012, 87:401-411.
6. Beghini A., Peterlongo P., Ripamonti C.B., Larizza L., Cairoli R., Morra E., Mecucci C. C-kit mutations in core binding factor leukemias. Blood 2000, 95:726-727.
7. Lim K.H., Pardanani A., Tefferi A. KIT and mastocytosis. Acta Haematol. 2008, 119:194-198.
8. Ronnstrand L. Signal transduction via the stem cell factor receptor/c-Kit. Cell. Mol. Life Sci.: CMLS 2004, 61:2535-2548.
9. Mol C.D., Lim K.B., Sridhar V., Zou H., Chien E.Y., Sang B.C., Nowakowski J., Kassel D.B., Cronin C.N., McRee D.E. Structure of a c-kit product complex reveals the basis for kinase transactivation. J. Biol. Chem. 2003, 278:31461-31464.
10. Kitayama H., Kanakura Y., Furitsu T., Tsujimura T., Oritani K., Ikeda H., Sugahara H., Mitsui H., Kanayama Y., Kitamura Y., et al. Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. Blood 1995, 85:790-798.
11. Tsujimura T., Furitsu T., Morimoto M., Isozaki K., Nomura S., Matsuzawa Y., Kitamura Y., Kanakura Y. Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation. Blood 1994, 83:2619-2626.
12. Patnaik M.M., Tefferi A., Pardanani A. Kit: molecule of interest for the diagnosis and treatment of mastocytosis and other neoplastic disorders. Curr. Cancer Drug Targets 2007, 7:492-503.
13. Ustun C., DeRemer D.L., Akin C. Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. Leuk. Res. 2011, 35:1143-1152.
14. Verstovsek S. Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression. Eur. J. Haematol. 2013, 90:89-98.
15. Verstovsek S., Tefferi A., Cortes J., O'Brien S., Garcia-Manero G., Pardanani A., Akin C., Faderl S., Manshouri T., Thomas D., Kantarjian H. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin. Cancer Res.: Official J. Am. Assoc. Cancer Res. 2008, 14:3906-3915.
16. Gleixner K.V., Mayerhofer M., Sonneck K., Gruze A., Samorapoompichit P., Baumgartner C., Lee F.Y., Aichberger K.J., Manley P.W., Fabbro D., Pickl W.F., Sillaber C., Valent P. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Haematologica 2007, 92:1451-1459.
17. Gleixner K.V., Peter B., Blatt K., Suppan V., Reiter A., Radia D., Hadzijusufovic E., Valent P. Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V. Haematologica 2013, 98:1450-1457.
18. Kosmider O., Denis N., Dubreuil P., Moreau-Gachelin F. Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate. Oncogene 2007, 26:3904-3908.
19. Pan J., Quintas-Cardama A., Kantarjian H.M., Akin C., Manshouri T., Lamb P., Cortes J.E., Tefferi A., Giles F.J., Verstovsek S. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation. Blood 2007, 109:315-322.
20. Jin B., Ding K., Pan J. Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing beta-catenin signaling. Mol. Cancer Ther. 2014, 13:1217-1230.
21. Jin Y., Lu Z., Ding K., Li J., Du X., Chen C., Sun X., Wu Y., Zhou J., Pan J. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species. Cancer Res. 2010, 70:2516-2527.
22. Jin Y., Ding K., Li H., Xue M., Shi X., Wang C., Pan J. Ponatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFRalpha: roles of Mcl-1 and beta-catenin. Mol. Cancer 2014, 13:17.
23. Barker N., Clevers H. Catenins, Wnt signaling and cancer. BioEssays: News Rev. Mol. Cell. Dev. Biol. 2000, 22:961-965.
24. Behrens J., von Kries J.P., Kuhl M., Bruhn L., Wedlich D., Grosschedl R., Birchmeier W. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 1996, 382:638-642.
25. Kajiguchi T., Lee S., Lee M.J., Trepel J.B., Neckers L. KIT regulates tyrosine phosphorylation and nuclear localization of beta-catenin in mast cell leukemia. Leuk. Res. 2008, 32:761-770.
26. Cools J., DeAngelo D.J., Gotlib J., Stover E.H., Legare R.D., Cortes J., Kutok J., Clark J., Galinsky I., Griffin J.D., Cross N.C., Tefferi A., Malone J., Alam R., Schrier S.L., Schmid J., Rose M., Vandenberghe P., Verhoef G., Boogaerts M., Wlodarska I., Kantarjian H., Marynen P., Coutre S.E., Stone R., Gilliland D.G. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. New Engl. J. Med. 2003, 348:1201-1214.
27. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., Sawyers C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876-880.
28. Pardanani A., Elliott M., Reeder T., Li C.Y., Baxter E.J., Cross N.C., Tefferi A. Imatinib for systemic mast-cell disease. Lancet 2003, 362:535-536.
29. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 2009, 9:798-809.
30. Aichberger K.J., Mayerhofer M., Gleixner K.V., Krauth M.T., Gruze A., Pickl W.F., Wacheck V., Selzer E., Mullauer L., Agis H., Sillaber C., Valent P. Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412. Blood 2007, 109:3031-3041.